398 studies on Tirzepatide curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab indexes 12,748 published Tirzepatide COA source records from third-party laboratories, covering 1,778 publicly attributable vendor identities. Across 11,828 records with positive numeric purity, the arithmetic mean is 99.68%. 143 records report zero purity; these remain in the record count and are excluded from the positive-purity mean. 25 positive purity results are below 90%; 598 records report measured amount more than 10% below the label. The latest recorded test date is 2026-10-17. TitrateLab did not perform these laboratory tests. Source records are not unique batches, and vendor identity does not establish manufacturing role, product safety or overall quality.
As of 2026-10-19, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 5 mg | $6.50 | $5.50–$7.50 | $1.30 | 2 sources · 2 offers |
| 10 mg | $8.88 | $8.00–$9.50 | $0.89 | 4 sources · 4 offers |
| 15 mg | $9.67 | $8.50–$10.50 | $0.64 | 3 sources · 3 offers |
| 20 mg | $11.33 | $10.50–$12.00 | $0.57 | 3 sources · 3 offers |
| 30 mg | $15.00 | $12.50–$17.00 | $0.50 | 4 sources · 4 offers |
| 40 mg | $19.88 | $18.00–$23.00 | $0.50 | 4 sources · 4 offers |
| 50 mg | $22.25 | $22.00–$22.50 | $0.45 | 2 sources · 2 offers |
| 60 mg | $26.12 | $25.00–$27.50 | $0.44 | 4 sources · 4 offers |
| 100 mg | $35.00 | $35.00–$35.00 | $0.35 | 1 source · 1 offer |
| 120 mg | $37.00 | $37.00–$37.00 | $0.31 | 1 source · 1 offer |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. View full price methodology →
All published source records, including absent and zero purity. Matching uses a case-insensitive exact peptide token. No deduplication in the headline; vendor rankings deduplicate eligible certificates separately. The COA archive can use normalized compound names and a different measurement or duplicate policy; totals from these populations need not match.
Latest recorded test: 2026-10-17. Aggregate calculated: 2026-10-19T03:55:46.655709+00:00. Calculation time is not a laboratory observation date.
Within that total, 3063 source records have unresolved vendor identity. They remain in corpus-level lab evidence and are excluded from named-vendor rankings.
Eligible vendors have at least 2 deduplicated certificates and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and certificate count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes submitted-sample evidence, not every product or shipment, and is not an endorsement.
| Rank | Vendor | Deduplicated certificates | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 241 | 99.6% | 0 of 229 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #2 | 195 | 99.53% | 0 of 183 (0.0%) 0 0% / not detected · 0 wrong compound · 12 unclassified | Reveal with Pro → | |
| #3 | 136 | 99.78% | 0 of 96 (0.0%) 0 0% / not detected · 0 wrong compound · 40 unclassified | Reveal with Pro → |
Vendor identities are included with Pro. Record counts and lab measurements remain visible.
Recent source records: #120652 (99.93%) · #120647 (99.96%) · #120646 (99.94%) · #120632 (99.9%) · #120622 (99.91%) · #120576 (99.8%)
This analysis provides compelling evidence that **tirzepatide offers a significant pharmacotherapeutic option for primary CVD prevention in obese Japanese adults, extending beyond its known weight loss benefits.** The…
Tirzepatide significantly lowered HbA1c in 107 non-obese Japanese T2D patients over 6 months. BMI reduction was more pronounced in higher baseline BMI groups.
**This review reinforces semaglutide's position as a cornerstone therapy for metabolic disorders, guiding clinicians and informed users on its optimal application and emerging benefits.** It highlights how **semagluti…
This study provides a critical, data-driven perspective on **GLP-1 RA** safety, particularly highlighting potential interactions with common herbal supplements. **Patients using GLP-1 RAs for obesity should exercise c…
A Phase 1/2a study evaluated the safety, tolerability, pharmacokinetics, pharmacodynamics, and body weight effects of **RN3161 (LY3841136)** as monotherapy and combined with **tirzepatide**.
**Anti-obesity pharmacotherapy** represents a significant advance in managing **obesity** and its comorbidities. While this abstract doesn't detail specific findings, understanding the impact of these agents on inflam…
If successful, this research could significantly broaden the perceived benefits of **semaglutide** and **tirzepatide** beyond weight loss and glycemic control, particularly for **postmenopausal women**. **Understandin…
**GLP-1 RAs are not currently approved or guideline-recommended for fertility restoration**, despite promising findings. This review highlights their potential to address underlying metabolic and hormonal dysfunctions…
GLP-1 RAs and dual GIP/GLP-1 agonists represent a potent therapeutic option for **pediatric obesity**, offering significant BMI reductions. **Clinicians should consider these agents for eligible children and adolescen…
This framework provides a crucial blueprint for clinicians and individuals using **GLP-1RA** or **dual incretin** therapies, offering actionable strategies to enhance treatment efficacy and tolerability. **Adopting a …
This review underscores an urgent need for robust policy enforcement and systemic changes to mitigate **alcohol-related harm** in Europe. **Implementing evidence-based alcohol policies, such as increased taxation, min…
These real-world findings reinforce that **tirzepatide offers a metabolically favorable weight loss profile, prioritizing fat reduction while relatively preserving lean muscle mass**. For individuals managing **obesit…
This innovative `TAPS-ASAL` method represents a significant leap forward in peptide manufacturing, offering a **scalable, sustainable, and cost-effective route** for producing complex therapeutic peptides. For the bio…
If successful, this trial could **revolutionize fertility-sparing treatment for endometrial cancer** by integrating a potent weight-loss medication directly into the therapeutic strategy. Current progestin-only approa…
If successful, this pilot trial could **redefine treatment strategies for individuals with co-occurring Alcohol Use Disorder and overweight/obesity**. Currently, therapeutic options that effectively address both condi…
This study provides crucial `CGM`-based evidence supporting the use of **GLP-1 receptor agonists** or **GLP-1/GIP dual agonists** as adjunct therapy for insulin-treated **type 2 diabetes** patients fasting during Rama…
The emergence of effective pharmacological options for **Obstructive Sleep Apnea Syndrome (OSAS)** represents a critical advancement for patients struggling with compliance to traditional therapies like CPAP. **This r…
**Tirzepatide's potential to induce intestinal healing in Crohn's disease represents a significant shift from current inflammation-centric treatments.** If successful, this study could pave the way for a new therapeut…
This systematic review provides crucial validation for the use of incretin-based therapies and `SGLT2` inhibitors in managing **MASH**, marking a significant shift in treatment paradigms. **Clinicians now have robust …
This analysis highlights a critical, unaddressed public health challenge: the increasing exposure of reproductive-aged women to **GLP-1 RAs** and the unknown impact on pregnancy outcomes. **Clinicians must prioritize …
Disproportionality analysis of FAERS data indicates a significant association between GLP-1 RAs and alopecia reporting, warranting further investigation.
This case report suggests that **rapid weight loss induced by GLP-1 RAs like tirzepatide might be a contributing factor to peripheral neuropathies such as brachial plexopathy**. For clinicians and individuals undergoi…
This first-in-human study of ARO-ALK7 marks a significant step towards potentially introducing a novel mechanism for **obesity** and **Type 2 Diabetes Mellitus** treatment. If successful, `ALK7` inhibition could offer…
This study provides crucial real-world safety data, indicating that the risk of **optic ischaemic neuropathy** is not a uniform class effect across all incretin-based therapies. **Clinicians and patients using semaglu…
The landscape for **Obstructive Sleep Apnea (OSA)** management is undergoing a significant transformation, moving beyond symptomatic treatment with CPAP to address the underlying **obesity** and metabolic drivers. **C…
This review solidifies the role of GLP-1RAs as a cornerstone therapy for patients with **MASLD**, especially those with co-existing obesity, type 2 diabetes, advanced fibrosis, or heart failure. The dual benefit of im…
This study demonstrates that integrating a virtual behavioral program with **semaglutide/tirzepatide** via telemedicine can lead to substantial improvements in psychosocial well-being for individuals with obesity. **F…
This review reaffirms that **dulaglutide** remains a valuable option in cardiometabolic care, not superseded but rather complementary to newer agents. For clinicians and patients, this means **dulaglutide** offers a p…
This systematic review provides compelling evidence that GLP-1RAs extend their therapeutic utility beyond metabolic disorders to significantly improve outcomes in **respiratory diseases**. For individuals with **obstr…
If successful, this study could significantly expand the therapeutic utility of **Tirzepatide** beyond **Type 2 Diabetes**. For individuals with **Type 1 Diabetes** struggling with **insulin resistance** and weight ga…
**Ensuring consistent drug delivery across various injection devices is crucial for the widespread adoption and patient safety of tirzepatide.** If the study confirms pharmacokinetic and safety similarity, it provides…
Two new studies will evaluate the feasibility and value of incorporating individualized diabetes risk prediction models into primary care for people with prediabetes.
**For individuals discontinuing GLP-1 RA therapy, this review highlights the urgent need for structured, evidence-based protocols to prevent weight regain.** Clinicians currently lack clear guidance on how to support …
Leading medical societies issued a joint advisory detailing nutritional strategies to support GLP-1 receptor agonist therapy for obesity and improve patient outcomes.
Research investigates the impact of long-acting incretin-based therapies like **semaglutide** and **tirzepatide**, delivered via telemedicine, on psychosocial outcomes in obesity management.
This model-based analysis provides a crucial quantitative framework for **individualized treatment decisions** in **Type 2 Diabetes** and obesity, especially where direct head-to-head trials are unavailable. For clini…
Identifying this specific obesity subphenotype with reduced endogenous GLP-1 synthesis and enhanced **tirzepatide** response represents a significant step towards precision medicine in obesity management. **This findi…
This review highlights that **semaglutide** and **tirzepatide** may offer multiple benefits for adults with autoimmune diabetes who retain residual **beta-cell function**, particularly those with **LADA**. For clinici…
This case report suggests that **Tirzepatide, when used after psychotherapy, may be a safe and effective option for individuals with binge-eating disorder and obesity**, potentially leading to both ED remission and si…
**This case report suggests a powerful new strategy for tackling complex periprosthetic fracture nonunions, especially in medically fragile patients.** The integration of a biomimetic hematoma scaffold delivering **rh…
This pharmacovigilance study provides crucial insights into the real-world safety profile of tirzepatide, particularly concerning ketoacidosis-spectrum events. **Clinicians prescribing tirzepatide should counsel patie…
This commentary highlights a critical emerging safety signal for widely used GLP-1RA and GIP/GLP-1RA medications. **Clinicians must be aware of the possibility of hair loss occurring with GLP-1RAs** and proactively in…
Tirzepatide significantly reduced hepatic steatosis and inflammation in a mouse MASLD model, downregulating `CCL2/CCR2` and `PI3K-AKT` pathways.
This study provides compelling real-world evidence that **tirzepatide offers a potent non-surgical option for managing recurrent weight gain after bariatric procedures**. For individuals who have undergone BS or EBT b…
This extensive prospective cohort study is critical for understanding the real-world efficacy and safety of combining GLP-1 medications with structured digital health interventions. **The findings will inform optimal …
Self-administered **tirzepatide** led to starvation ketosis and subsequent anorexia nervosa diagnosis in a 21-year-old woman, highlighting risks of unsupervised use.
This study provides critical real-world evidence on the safety profile of GLP-1 based therapies, highlighting a statistically significant, albeit low absolute, increased risk of severe GI motility issues. **Clinicians…
This review underscores that **improving GLP-1RA adherence requires a holistic approach beyond simply managing side effects**. For peptide users and clinicians, it highlights the need to consider patient expectations,…
This case report suggests **tirzepatide may offer a promising therapeutic strategy for Smith-Magenis syndrome**, addressing both the challenging hyperphagia-driven obesity and severe behavioral dysregulation. This dua…
This preclinical finding suggests a novel therapeutic strategy for **opioid use disorder (OUD)**, particularly for fentanyl addiction. **Semaglutide**, already approved for diabetes and weight management, could be rep…
Free, no account — handy when you're working with Tirzepatide.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$14 monthly or $88/year
Create an account